
    
      This is an open-label, multi-center, randomized, Phase 3 study designed to compare the
      efficacy and safety of pegilodecakin in combination with FOLFOX versus FOLFOX alone in
      participants with metastatic adenocarcinoma of the pancreas who have progressed on one prior
      gemcitabine containing regimen.
    
  